"Tome Biosciences Expands Genome Editing Reach with Replace Therapeutics Acquisition"
Originally Published 2 years ago — by Endpoints News
Tome Biosciences, a gene editing company, has acquired Replace Therapeutics for $65 million upfront, with potential total payments reaching $185 million. This acquisition, shortly after Tome's launch with substantial funding, aims to enhance its DNA editing capabilities by integrating Replace's technology for making precise, smaller-scale changes to the genome. This complements Tome's existing CRISPR-based technology for inserting larger DNA sequences.